Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baseline Testosterone as a Prognostic and/or Predictive Biomarker in Metastatic Hormone Sensitive Prostate Cancer

NCT05530395 is registered in ClinicalTrials.gov with Ignacio Puche Sanz as lead sponsor.

NCT NCT05530395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05530395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baseline Testosterone as a Prognostic and/or Predictive Biomarker in Metastatic Hormone Sensitive Prostate Cancer
Lead sponsor
Ignacio Puche Sanz
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2023
Completion date
January 1, 2026
Enrollment
300 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic